Stockscreener 앱 받기
6.69
8.65%
0.54
전일 마감가:
$6.15
열려 있는:
$6.35
하루 거래량:
452.40K
Relative Volume:
0.54
시가총액:
$207.70M
수익:
-
순이익/손실:
$-29.25M
주가수익비율:
-5.6408
EPS:
-1.186
순현금흐름:
$-22.80M
1주 성능:
-5.09%
1개월 성능:
-11.50%
6개월 성능:
+73.56%
1년 성능:
+97.69%
1일 변동 폭
$6.35
$6.87
1주일 범위
$6.05
$7.1604
52주 변동 폭
$1.73
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
명칭
Sagimet Biosciences Inc
전화
(650) 561-8600
주소
155 BOVET RD., SUITE 303, SAN MATEO
SGMT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
6.6999 | 200.01M | 0 | -29.25M | -22.80M | -1.186 |
|
VRTX
Vertex Pharmaceuticals Inc
|
386.21 | 99.26B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.14 | 62.06B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.67 | 59.21B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
727.23 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
339.96 | 36.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-11 | 개시 | Wedbush | Outperform |
| 2025-08-07 | 재개 | H.C. Wainwright | Buy |
| 2025-07-24 | 개시 | Canaccord Genuity | Buy |
| 2024-12-06 | 개시 | Oppenheimer | Outperform |
| 2024-11-12 | 개시 | UBS | Buy |
| 2024-06-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-05-02 | 개시 | H.C. Wainwright | Buy |
| 2024-03-25 | 개시 | Leerink Partners | Outperform |
| 2023-08-08 | 개시 | Goldman | Buy |
| 2023-08-08 | 개시 | JMP Securities | Mkt Outperform |
| 2023-08-08 | 개시 | Piper Sandler | Overweight |
| 2023-08-08 | 개시 | TD Cowen | Outperform |
모두보기
Sagimet Biosciences Inc 주식(SGMT)의 최신 뉴스
Positive Phase 3 Results For Denifanstat For The Treatment Of Moderate To Severe Acne To Be Presented At The Eadv Congress 2025 By Partner Ascletis - TradingView
Sagimet Biosciences Reports Successful Phase 3 Trial Results for Denifanstat in Acne Treatment and Announces Phase 1 Trial of TVB-3567 - Quiver Quantitative
Positive Phase 3 Results for Denifanstat for the Treatment - GlobeNewswire
18.6% Treatment Success: Sagimet's Novel FASN Inhibitor Achieves Breakthrough in Phase 3 Acne Trial - Stock Titan
Sagimet Biosciences Inc.'s (NASDAQ:SGMT) market cap dropped US$22m last week; individual investors who hold 46% were hit as were institutions - simplywall.st
Aug Ideas: Is Sagimet Biosciences Inc stock trending bullish2025 Biggest Moves & Advanced Swing Trade Entry Alerts - خودرو بانک
Ideas Watch: Will GRFS outperform its industry peers2025 Investor Takeaways & Technical Pattern Alert System - خودرو بانک
Aug Mood: Can Sagimet Biosciences Inc continue delivering strong returnsWeekly Gains Report & Real-Time Volume Surge Alerts - خودرو بانک
Here's Why Sagimet Biosciences Inc. (SGMT) is Poised for a Turnaround After Losing 15.8% in 4 Weeks - Yahoo Finance
Aug EndMonth: Is Sagimet Biosciences Inc. stock a buy or sell2025 Winners & Losers & Free Expert Verified Stock Movement Alerts - خودرو بانک
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Dow Update: Is Sagimet Biosciences Inc. stock a good pick for beginners2025 Fundamental Recap & High Accuracy Investment Entry Signals - خودرو بانک
Market Leaders: Can Sagimet Biosciences Inc. continue delivering strong returnsEntry Point & Fast Gain Stock Trading Tips - خودرو بانک
Quarterly Risk: Is Sagimet Biosciences Inc stock influenced by commodity pricesJuly 2025 Chart Watch & Intraday High Probability Setup Alerts - خودرو بانک
Is Sagimet Biosciences Inc. stock entering bullish territory2025 Breakouts & Breakdowns & Risk Managed Investment Strategies - newser.com
What earnings revisions data tells us about Sagimet Biosciences Inc.2025 Biggest Moves & Smart Money Movement Tracker - newser.com
Applying big data sentiment scoring on Sagimet Biosciences Inc.2025 AllTime Highs & Risk Controlled Stock Alerts - newser.com
Wall Street Zen Downgrades Sagimet Biosciences (NASDAQ:SGMT) to Sell - MarketBeat
What momentum shifts mean for Sagimet Biosciences Inc.July 2025 Short Interest & Weekly Top Gainers Alerts - newser.com
Will Sagimet Biosciences Inc. continue its uptrendWeekly Market Summary & Comprehensive Market Scan Insights - newser.com
Will Sagimet Biosciences Inc. benefit from macro trendsWeekly Investment Recap & Weekly Return Optimization Plans - newser.com
will sagimet biosciences inc. continue its uptrendJuly 2025 Trade Ideas & Verified Short-Term Trading Plans - newser.com
Ranking Sagimet Biosciences Inc. among high performing stocks via toolsJobs Report & Smart Swing Trading Alerts - newser.com
Visual analytics tools that track Sagimet Biosciences Inc. performanceMarket Volume Report & Weekly Top Stock Performers List - newser.com
Should you wait for a breakout in Sagimet Biosciences Inc.July 2025 Summary & Risk Managed Investment Signals - newser.com
Can volume confirm reversal in Sagimet Biosciences Inc.July 2025 Retail & Capital Efficiency Focused Ideas - Newser
Forecasting Sagimet Biosciences Inc. price range with options data2025 Market Sentiment & Reliable Intraday Trade Alerts - Newser
What’s the recovery path for long term holders of Sagimet Biosciences Inc.Earnings Miss & Consistent Profit Trading Strategies - Newser
Does Sagimet Biosciences Inc. qualify in momentum factor screeningWeekly Loss Report & Community Verified Swing Trade Signals - Newser
Real time social sentiment graph for Sagimet Biosciences Inc.Global Markets & Risk Controlled Daily Plans - Newser
How to track smart money flows in Sagimet Biosciences Inc.Quarterly Profit Summary & Daily Volume Surge Signals - Newser
Will Sagimet Biosciences Inc. stock go up soonMarket Growth Report & Expert Approved Momentum Trade Ideas - Newser
Sagimet Biosciences (NASDAQ:SGMT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Alyeska Investment Group L.P. Trims Stock Position in Sagimet Biosciences Inc. $SGMT - MarketBeat
Sagimet Biosciences to Present at the 9th Annual MASH Drug Development Summit on Innovations in Metabolic Dysfunction and Fibrosis Treatment - Quiver Quantitative
Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit - GlobeNewswire
Novel MASH Treatment Data: Sagimet's Denifanstat Shows Anti-Fibrotic Effects in Advanced Patients - Stock Titan
Price action breakdown for Sagimet Biosciences Inc.July 2025 Big Picture & Smart Allocation Stock Tips - Newser
Will Sagimet Biosciences Inc. Benefit From Broader Market BounceJuly 2025 Setups & Daily Entry Point Trade Alerts - beatles.ru
Can Sagimet Biosciences Inc. continue delivering strong returnsJuly 2025 Closing Moves & Comprehensive Market Scan Reports - beatles.ru
Wall Street Zen Upgrades Sagimet Biosciences (NASDAQ:SGMT) to “Hold” - Defense World
Is Sagimet Biosciences Inc. attractive at current valuation2025 Volume Leaders & Weekly Watchlist of Top Performers - خودرو بانک
Sagimet Biosciences shares fall 1.55% after-hours following presentation at Cantor Global Healthcare Conference. - AInvest
What indicators show strength in Sagimet Biosciences Inc.July 2025 Analyst Calls & Safe Capital Growth Plans - Newser
Sagimet Biosciences’ Strategic Positioning in the Biotech Sector - AInvest
Sagimet Biosciences Presents at Cantor Global Healthcare Conference 2025 - AInvest
Transcript : Sagimet Biosciences Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-03-2025 01 - MarketScreener
Sagimet Biosciences Inc.’s volatility index tracking explainedWeekly Trade Report & Smart Investment Allocation Tips - Newser
Is Sagimet Biosciences Inc. stock bottoming outGlobal Markets & Risk Adjusted Swing Trade Ideas - Newser
Is Sagimet Biosciences Inc. a strong candidate for buy and hold2025 Retail Activity & Smart Allocation Stock Tips - خودرو بانک
News impact scoring models applied to Sagimet Biosciences Inc.Portfolio Gains Summary & Daily Growth Stock Investment Tips - Newser
Sagimet Biosciences Inc (SGMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Sagimet Biosciences Inc 주식 (SGMT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Martins Eduardo Bruno | Chief Medical Officer |
Jul 21 '25 |
Sale |
9.13 |
8,277 |
75,607 |
106,936 |
| Rozek Elizabeth | General Counsel and CCO |
Jul 21 '25 |
Sale |
9.13 |
10,780 |
98,471 |
183,726 |
0.17%
0.47%
자본화:
|
볼륨(24시간):